MaaT Pharma SA (EPA:MAAT)
France · Delayed Price · Currency is EUR 1.010
-0.020 (-1.94%)
Oct 2, 2026, 5:35 PM CET
MaaT Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3.18 | 4.52 | 3.22 | 2.23 | 1.43 | 0.97 |
| 3.18 | 4.52 | 3.22 | 2.23 | 1.43 | 0.97 | |
Revenue Growth | -19.02% | 40.67% | 44.34% | 55.80% | 47.12% | - |
Cost of Revenue | 1.04 | 1.73 | 1.61 | 0.88 | 0.64 | 0.33 |
Gross Profit | 2.13 | 2.8 | 1.6 | 1.35 | 0.79 | 0.64 |
Selling, General & Admin | 6.9 | 8.18 | 6.88 | 5.38 | 4.43 | 2.92 |
Research & Development | 33.09 | 28.67 | 26.88 | 20.49 | 13.98 | 8.96 |
Other Operating Expenses | -3.87 | -4.32 | -3.72 | -4.58 | -4.06 | -2.34 |
Operating Expenses | 36.12 | 32.53 | 30.03 | 21.29 | 14.34 | 9.54 |
Operating Income | -33.98 | -29.73 | -28.43 | -19.94 | -13.56 | -8.89 |
Interest Expense | -1.64 | -1.26 | -0.87 | -0.4 | -0.19 | -0.12 |
Interest & Investment Income | 1.39 | - | - | - | 0.05 | - |
Other Non Operating Income (Expenses) | -0.07 | -0.07 | 0.39 | 0.63 | -0.02 | -0.01 |
Pretax Income | -34.31 | -31.06 | -28.9 | -19.72 | -13.71 | -9.02 |
Net Income | -34.31 | -31.06 | -28.9 | -19.72 | -13.71 | -9.02 |
Net Income to Common | -34.31 | -31.06 | -28.9 | -19.72 | -13.71 | -9.02 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | - | 16 | 13 | 11 | 10 | 2 |
Shares Outstanding (Diluted) | - | 16 | 13 | 11 | 10 | 2 |
Shares Change | - | 21.97% | 14.95% | 14.89% | 307.65% | 135.06% |
EPS (Basic) | - | -1.95 | -2.21 | -1.73 | -1.39 | -3.72 |
EPS (Diluted) | - | -1.95 | -2.21 | -1.73 | -1.39 | -3.72 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -16.33 | -22.79 | -19.76 | -13.27 | -8.17 |
Free Cash Flow Per Share | - | -1.02 | -1.75 | -1.74 | -1.34 | -3.37 |
Gross Margin | 67.16% | 61.80% | 49.81% | 60.59% | 55.11% | 66.05% |
Operating Margin | -1070.03% | -657.14% | -883.95% | -895.11% | -947.97% | -914.92% |
Profit Margin | -1080.19% | -686.58% | -898.76% | -884.96% | -958.95% | -927.88% |
Free Cash Flow Margin | - | -360.88% | -708.77% | -887.03% | -927.76% | -840.23% |
EBITDA | -33.6 | -29.41 | -28.2 | -19.74 | -13.32 | -8.71 |
D&A For EBITDA | 0.38 | 0.32 | 0.23 | 0.2 | 0.24 | 0.18 |
EBIT | -33.98 | -29.73 | -28.43 | -19.94 | -13.56 | -8.89 |
Advertising Expenses | - | 0.22 | 0.25 | 0.24 | 0.19 | 0.15 |